COMPASS Pathways plc established its first Centre of Excellence in collaboration with The Sheppard Pratt Institute for Advanced Diagnostics and Therapeutics in Baltimore, Maryland. Led by Scott Aaronson M.D., director of clinical research at Sheppard Pratt, the center is intended to accelerate consumer access to evidence-based innovation in mental health treatment. It will function as a research facility and innovation lab to generate evidence to shape therapy models in mental health care, train and certify therapists, conduct clinical trials including proof-of-concept studies, and prototype digital solutions to improve consumer experience.
The center will be built on the Sheppard Pratt Towson campus and will include at least four state-of-the-art psychedelic therapy rooms, as well as facilities for research and training. In addition to a capital investment to support the design and building work, COMPASS will fund research studies into psilocybin therapy and other therapies. The first wave of research will focus on COMPASS’s investigational COMP360 psilocybin therapy, which comprises administration of COMP360 psilocybin with psychological support from specially trained therapists.
Sheppard Pratt is a research institute in mental health and is one of the top psychiatric hospitals in the United States. It is a leader in clinical service delivery, supporting more than 70,000 consumers annually in its local community, as well as across 42 states and 19 countries.
COMPASS Pathways plc is a mental health care company dedicated to accelerating consumer access to evidence-based innovation in mental health to treat people who are not helped by current treatments. It is developing a new model of synthetic psilocybin, COMP360, which has been designated a Breakthrough Therapy by the US Food and Drug Administration (FDA), for treatment-resistant depression. COMPASS is currently conducting a phase IIb clinical trial of psilocybin therapy for TRD, in 21 sites across Europe and North America.
This was reported by COMPASS Pathways plc and Sheppard Pratt on January 8, 2021.
Contact information: Tamara Chumley, Director of Public Relations and Communications, Sheppard Pratt, 6501 N. Charles Street Baltimore MD 21204; 410-938-3157; Email: email@example.com; Website: https://www.sheppardpratt.org/